Spyre Therapeutics gets UBS buy rating with $120 target price
SYRE•UBS initiated coverage of Spyre Therapeutics with a buy rating and a $120 target price.
Related News
Invitation Homes Inc.: UBS cuts target price to $31 from $35
INVH•
UL Solutions raises target price to $97 from $96
ULS•
American Homes 4 Rent: UBS cuts target price to $32 from $35
AMH•
What is the diesel deal between Putin and Trump?
USO•
UBP says bull market broadens as inflation risks keep Fed hike on table
SPY•